Deregulation of Wnt signalling has recently been implicated in human renal cancer. Here, we directly test this association by using a Cre-LoxP strategy to inactivate the Adenomatous Polyposis Coli (Apc) gene in the murine renal epithelium. Mice homozygous for a conditional Apc allele were intercrossed with mice transgenic for Cre recombinase under control of the Cyp1A promoter, which delivers constitutive recombination within a proportion of cells in the renal epithelium. Inactivation of Apc leads to the accumulation of nuclear b-catenin and the rapid development of multiple dysplastic foci. Renal carcinoma was observed with an earliest onset of 4 months. This predisposition was accelerated by p53 deficiency, reducing the earliest onset to 2 months. Compared to other murine models of kidney neoplasia, this represents particularly rapid onset of disease, and so implicates an important role for Apc in suppressing renal carcinoma.
The Adenomatous Polyposis Coli (APC) gene was identified through its role as a tumour suppressor in the human colorectum. Germline mutations of APC characterise the Mendelian dominant inherited disorder, familial adenomatous polyposis coli (FAP) (Kinzler et al., 1991) , and FAP patients develop numerous adenomas within the large intestine, some of which ultimately progress to carcinoma. Although therefore defined as a tumour suppressor within the human intestine, it is clear that APC mediates tumour suppression within other cell types, for example in the mammary gland (Furuuchi et al., 2000) . In the kidney, a role for APC in a subset of renal cell carcinomas has been suggested through reported loss of heterozygosity and reduced protein expression (Pecina-Slaus et al., 1999) . One predicted consequence of loss of APC function is an elevation in the levels of b-catenin, as in the absence of Apc it is no longer phosphorylated and is not targeted for destruction by the proteosome. Deregulation of b-catenin levels is clearly important to normal kidney physiology, as expression of an activated form of b-catenin has been shown to lead to the rapid development of polycystic kidney disease (Saadi-Kheddouci et al., 2001) .
A clear correlation is emerging between deregulated Wnt signalling and the development of Wilms' tumours. Thus, nuclear accumulation of b-catenin has been reported to occur at high frequency in Wilms' tumours (Koesters et al., 2003) , and two independent groups have reported frequent mutation of the b-catenin gene (Koesters et al., 1999; Kusafuka et al., 2002) . These reports describe nuclear immunoreactivity for b-catenin even in the absence of detectable b-catenin mutations, suggesting that Wnt deregulation may also be occurring through other mechanisms. The latter notion is supported by the observation of elevated levels of the Wnt antagonist Dickkopf-1 in a high percentage of Wilms' tumours (Wirths et al., 2003) .
In adult renal cell carcinoma, different studies have produced contradictory evidence for deregulation of b-catenin levels. Zang et al. (2001) have reported elevated levels of b-catenin, but other studies have reported only a weak or absent association (Bilim et al., 2000; Zhu et al., 2000) . Contrasting data have also emerged from a study by Guo et al. (2001) , who reported downregulation of b-catenin in low nuclear grades of renal cell cancer, but increased levels of b-catenin in both papillary and chromophobe renal cancers.
These observations suggest a role for deregulated Wnt signalling in kidney neoplasia. To directly address this possibility we analysed the phenotype of mice in which the Apc gene is deleted within the renal epithelium. Using this approach, we show that loss of Apc leads to the nuclear relocalisation of b-catenin and to the early onset of renal cell carcinoma, and that this oncogenesis is accelerated in a p53-deficient background.
Mice transgenic for the Cre recombinase under the control of the Cyp1A promoter, termed AhCre, have been described previously Sansom et al., 2004) . These mice are characterized by inducible expression of Cre recombinase (following exposure to the agent b-napthoflavone) within both the gastrointestinal tract and the liver. However, in the absence of inducer, the AhCre transgene also drives Cre-mediated recombination in other tissues. To define the pattern of recombination obtained in the kidney, mice were generated which were transgenic for both the AhCre transgene and the Rosa26 reporter locus. In this cross, recombination is reported at the cellular level through upregulation of LacZ following Cre-mediated deletion of a LoxP flanked STOP cassette. Frequent LacZ positive cells were observed within the both the embryonic (E14.5 and E18.5) and adult renal tubular epithelium, within the collecting ducts and the glomerulus (Figure 1) . Notably, within the embryonic kidney we observed recombination within both comma-and sshaped bodies, which are developmental precursors of the adult renal tubular epithelium (Figure 1i and j) . These data indicates frequent Cre-mediated recombination within multiple kidney cell types from as early as E14.5.
To define the effects of loss of Apc function within the kidney, mice bearing a LoxP flanked Apc allele were intercrossed with mice bearing the AhCre transgene. Mice homozygous for the floxed Apc allele and carrying the AhCre transgene (AhCre þ Apc fl/fl ) were generated and allowed to age. At 9 months of age a proportion of mice developed overt signs of disease and were killed. Necropsy showed macoscopically visible nodules in 5/17 animals ( Figure 2 ).
Histological examination of H&E stained kidney sections showed multiple tumours of sizes from 50 mm diameter up to 9.6 mm. All consisted of tubules lined with dysplastic epithelium with scanty eosinophilic cytoplasm and hyperchromatic pleomorphic nuclei with frequent mitotic figures. There was a continuum of morphological architecture from small dysplastic foci to large tumours with multilayered epithelium. In many, particularly the larger tumours, some of the tubules had become cystic, with cysts often dominating the histological picture (Figure 2b and c). Transmission electron microscopy of tissue recovered from a paraffin block containing a 1 mm tumour showed that the tumour tubule lining cell retained many of the ultrastructural features of the normal proximal tubule cell including a microvillous brush border (Figure 2e and f). The morphological appearances, both at light and electron microscopy, were strikingly similar to human conventional renal cell carcinoma particularly with regard to the tubulo-cystic architecture and the microvilli. The small tumours and the small dysplastic foci were located at the corticomedullary junction. A serial section of one of these foci demonstrated it to be in continuity with the proximal tubules and the descending loop of Henle (Supplementary Figure) . These features strongly suggest a specific site of origin from the epithelium at the distal end of the proximal convoluted tubule. The frequency of Figure 1 The pattern of AhCre-mediated recombination in kidneys derived from adult The pattern of recombination in E14.5 and E18.5 kidneys, respectively. (i, j) High-power magnification of the pattern of recombination observed in comma-and s-shaped bodies in E13.5 kidneys these tumours was much lower than the frequency of recombination reported by the LacZ allele in wild-type (wt) mice. This may reflect a lower frequency of recombination at the Apc allele, the requirement for both Apc alleles to undergo recombination, or that the majority of Apc-deficient cells fail to progress to form a tumour.
To further define the time of onset of tumorigenesis, groups of Apc fl/fl ,AhCre þ mice were killed at 2 (n ¼ 21), 4 (n ¼ 22) and 6 (n ¼ 11) months. The earliest detected carcinomas were observed at four months, with an increased incidence at 6 months ( Figure 3) . No tumours were found in control mice. To confirm Cre-mediated recombination had occurred within the tumours, we performed PCR analysis of DNA derived from both normal and tumour material, which confirmed the presence of the recombined Apc allele within all tumours analysed (Figure 2) .
We next investigated the pattern of b-catenin dysregulation within both diseased and apparently normal kidneys from AhCre þ Apc fl/fl mice. This revealed elevated, nuclear b-catenin in both the carcinomas and (Shibata et al., 1997) , the Rosa 26 LacZ reporter allele (Soriano, 1999 ) and a p53 null allele (Clarke et al., 1993) . Progeny from this cross were intercrossed to derive an outbred colony, segregating for the C57BL6J, S129SV and C3H genomes at a ratio of 75, 12.5 and 12.5%, respectively. (Shibata et al., 1997) to detect a 258 base pair product specific to the recombined allele. T, independent tumour samples; N, macroscopically normal tissue from the AhCre þ ,Apc fl/fl mice; wt DNA from a wild-type control kidney. Recombination was only observed in the tumour samples. (e, f) Tumour and adjacent renal tissue recovered from paraffin wax and processed for electron microscopy; (e) shows a normal proximal tubule showing well-preserved microvillous brush border, abundant mitochondria and regular nuclei, (f) tumour cells forming a duct. There are partly formed but readily identified microvilli on the luminal surface. Nuclei are irregular and have folded membranes; moderate numbers of mitochondria are present. These features demonstrate strong similarities between the proximal tubule and the tumour cell strongly supporting this structure as the origin of the tumour. (g-j) Immunohistochemical analysis of b-catenin expression showing elevated levels of nuclear b-catenin in isolated tubular cells (g), small dysplastic foci (h) and in renal cell cancer (i, j). Immunohistochemistry for b-catenin (1 : 50, Transduction labs) was performed on sections fixed in formaldehyde for no longer than 24 h prior as previously described (Batlle et al., 2002; Gallagher et al., 2002) dysplastic foci (Figure 2) , and also identified single renal cells with elevated levels of nuclear b-catenin. Again, the frequency and pattern of b-catenin nuclear positivity was markedly reduced compared to the pattern of recombination described by the Rosa26 reporter allele in wt mice. As a result of the association between anaplastic Wilms' tumorigenesis and loss of p53 (Bardeesy et al., 1994) , we next intercrossed the AhCre þ Apc fl/fl mice onto a p53 deficient background (Clarke et al., 1993) þ / þ mutant controls, 17 were male, of which none developed cancer at this time point. Thus, the altered tumour predisposition of the double nulls does not occur as a consequence of sex differences. Notably, we also did not observe any renal tumorigenesis or foci development within any p53 À/À mice aged to six months. The renal cell carcinomas that developed in the combined Apc fl/fl p53 À/À mice showed more marked nuclear atypia than those arising on the Apc fl/fl p53 þ / þ background, with focal necrosis and dedifferentiation to an anaplastic phenotype (Figure 3 ). Smaller dysplastic foci were again observed in tumour bearing kidneys, and were also observed in a proportion (3/10) of mice which had apparently tumour free kidneys. We next examined the effects of heterozygosity for p53, with cohorts examined at 2 (n ¼ 8), 4 (n ¼ 12) and 6 (n ¼ 7) months of age. This produced an intermediate phenotype, with the earliest onset of renal cell carcinoma at 2 months of age (1/8), at which point a further 3/8 showed dysplastic foci upon histological examination. At the later time points of 4 and 6 months the incidence of renal cell cancer rose to 5/12 and 4/7, respectively. No further dysplastic foci were seen in the tumuor free mice. Notably, no renal lesions were observed in 15 p53 þ /À control mice aged to 9 months.
The relatively low number of dysplastic foci observed in the AhCre þ Apc fl/fl mice, together with the observed acceleration of phenotype in the absence of p53 prompted us to investigate whether the majority of Apc-deficient cells were being deleted in a p53-dependent manner. To test this hypothesis, we examined the pattern of b-catenin
mice, we observed a marked increase in the incidence of cells showing b-catenin nuclear positivity (Figure 3 ). This indicates that in the absence of p53, Apc null cells are preferentially retained. We hypothesize that this reflects at least partial reliance upon p53 for the spontaneous deletion of Apc null cells. Thus, providing a direct mechanism for enhanced neoplasia in the absence of p53. It remains likely that p53 deficiency is accelerating tumorigenesis in this model by additional mechanisms, notably enhanced genomic instability as evidenced by the severe nuclear atypia in the doubly mutant mice (Figure 3) .
At present there is a paucity of murine models of renal cell carcinoma. Indeed, a number of genetics studies attempting to recapitulate kidney tumorigenesis in mice by inactivating human tumour suppressor genes have failed. Neither heterozygosity of VHL (which is silenced or mutated in 50% of renal cell carcinoma) or WT1 leads to kidney tumorigenesis in mice (Menke et al., 2002; Kleymenova et al., 2004) . The few models that do develop RCC have relatively long latency times of 10-15 months (Kobayashi et al., 1999 (Kobayashi et al., , 2001 Onda et al., 1999) . The finding that combined loss of p53 and Apc induces RCC in as little as 2 months starkly contrasts with these existing models. Therefore, we have provided the first definitive link showing that loss of Apc clearly predisposes to renal neoplasia and thus implicate Wnt deregulation in the development of human renal neoplasia. Consistent with this prediction is that there is an emerging correlation between deregulated Wnt signalling and the development of Wilms' tumours; however, the data for RCC remains less clear.
Our model contrasts somewhat with a recent report from Qian et al. (2005) , which used the same Lox-P flanked Apc allele in conjuction with a Ksp-Cre transgene. Double transgenics did not survive long after birth, and were characterized by cystic renal neoplasia rather than the renal carcinoma we observe. This difference is presumably a reflection of the pattern of Cre-mediated recombination, either because the AhCre and Ksp-Cre transgenes target different cells within the kidney, or because the shorter lifespan of the KspCre þ Apc fl/fl mice precludes progression to carcinoma. One prediction from our data is of increased predisposition to RCC in FAP patients; however, such a correlation has not yet been identified. We hypothesize that this apparent failure reflects a requirement for a 'permissive' environment which allows the retention of Apc deficient cells. Thus, we show that the generation of many Apc null cells in an otherwise wt kidney results in only a relatively small number of RCC; yet this predisposition is enhanced by the increased retention of Apc null cells within a deficient p53 environment. This interpretation is further supported by the failure to observe either Wilms' tumours or RCC in the Apc Min mouse, which suggests that there is effective deletion of Apc null cells from the renal epithelium. Thus, Apc deficiency is unlikely to be an initiating event in renal cell cancer by virtue of the high-frequency deletion of null cells; rather, loss of Apc is likely to be an important factor within a permissive environment, such as following loss of p53 or perhaps WT1.
These relationships remain to be fully explored, but it is implicit that mutations which foster the generation and survival of Apc null cells within the renal epithelium will predispose to RCC. Our results therefore confirm a role for Apc in preventing renal cell carcinoma in the mouse, and raise the possibility that deregulated Wnt signalling is an important mechanism in human RCC. Furthermore, we indicate that this process is at least partially suppressed by p53-mediated deletion of Apc deficient cells.
